- Business
- BSF Enterprise Plc BSF Enterprise Plc (BSFA.L) is a United Kingdom-based biotechnology company that develops and commercializes cell-based tissue-engineered solutions addressing global challenges in deforestation, hunger, environment, health, and animal cruelty; its principal activity involves acquiring and advancing businesses in biotechnology sectors with a focus on lab-grown leather, cultivated meat, and corneal repair technologies. Incorporated in 2018 and headquartered at 2 Portman Street, London, W1H 6DU, the company operates through wholly owned subsidiaries including 3D Bio-Tissues Limited (3DBT), which provides patented platforms for generating structured tissues, serum-free media supplements like City-Mix™ and CytoBoost™ to enhance cell performance in biopharma, cultivated meat, and tissue production; Lab-Grown Leather Limited (LGL), which produces scaffold-free, 2mm-thick lab-grown leather from immortalized horse cells for fashion, automotive, and accessories using animal-free processes; Kerato Limited, which develops bio-equivalent corneal tissues and in-situ gelling LiQD Cornea technology for veterinary and human ophthalmic repair; Cultivated Meat Technologies Limited (CMT), which advances scaffold-free cultivated meat production; and BSF Enterprise (Hong Kong) Limited (BSF HK), which supports market entry in Greater China for sustainable proteins. The company's core offerings emphasize ethical, sustainable alternatives to animal-derived products, targeting biopharma, cellular agriculture, regenerative medicine, luxury fashion brands, and healthcare markets across the UK, Europe, Asia, and North America; products feature structurally identical leather showcased at Future Fabrics Expo 2024, corneal implants reducing donor reliance, and media additives minimizing animal serum use while enabling cost-effective scaling. Recent developments include a December 2024 oversubscribed £500,000 fundraising via 20 million shares at 2.5p with warrants to fund pilot leather production, CytoBoost™ commercialization, veterinary corneal trials in 2025, and Greater China expansion; a January 2025 strategic Memorandum of Understanding with Sartorius for scalable lab-grown leather and protein bioprocessing; February 2024 MoU with Maison Amelie Pichard for lab-grown leather fashion accessories; March 2024 commercial agreement and City-Mix™ testing with Ivy Farm Technologies for Asian cultivated meat; April 2024 Heads of Terms and research partnership with University of Montreal for liquid cornea licensing; Innovate UK grants for leather tanning with University of Northampton and ocular toxicity models with Newcastle University; and ongoing collaborations with luxury fashion houses yielding minimal viable leather products and over £50,000 in partnership payments as of early 2025.